# Imatinib Mesylate in Treating Patients With Salivary Gland Cancer

> **NCT00045669** · PHASE2 · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 16 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** imatinib mesylate

## Key facts

- **NCT ID:** NCT00045669
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-07
- **Primary completion:** 2004-01
- **Final completion:** 2005-01
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2019-02-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00045669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00045669, "Imatinib Mesylate in Treating Patients With Salivary Gland Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00045669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*